Exchange: NASDAQ·Updated 07:34 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 12Pre-Market

Estimated EPS

-$0.11

Estimated Rev

$0.62M

$TSHA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 down -50.00% YoY • Taysha Gene Therapies expects its $276.6 million cash and cash equivalents as of March 31, 2026, to fund operations into 2028, but will require additional capital for R&D and commercialization.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.11
--
--
N/A
Q1 '26
-$0.10
-$0.12
-24.14%
MISSED
Q4 '25
-$0.10
-$0.08
16.32%
BEAT
Q3 '25
-$0.09
-$0.09
-1.01%
MISSED
Q2 '25
-$0.08
-$0.09
-15.57%
MISSED

Advertisement|Remove ads.